Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...
The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...
Current guideline recommendations for the use of beta-blockers after myocardial infarction without reduced ejection fraction are based on trials conducted before routine reperfusion, invasive care, ...
The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of ...
MADRID, Spain—Two randomized, controlled trials testing beta-blockers in post-MI patients without heart failure or impaired left ventricular ejection fraction added a bit of confusion to a field ...
Tectonic Therapeutic reported positive Phase 1b trial results for TX45, showing improved hemodynamics in PH-HFpEF patients without serious adverse events. Despite the positive results, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results